Published in Medical Letter on the CDC and FDA, February 7th, 2000
This 2-dose regimen of 10 mcg/1.0 mL is an alternative to the 3-dose 5 mcg/0.5 mL regimen of Recombivax HB already used in children 0 to 19 years of age.
"Adolescents can be the hardest age group to fully vaccinate for hepatitis B," said Tom Vernon, MD, vice president, Public Health and Medical Affairs, Merck Vaccine Division. "Busy schedules leading to missed or postponed appointments, changes in physicians and healthcare plans and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.